ATLANTA – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology firm focused on developing vaccines and immunotherapies for cancers and infectious diseases, has announced the strengthening of its intellectual property portfolio with multiple patents granted by global patent offices. The Japanese Patent Office has allowed a patent application for the company’s immunotherapy program targeting tumor-associated antigens, specifically involving recombinant viral vectors containing MUC-1 nucleic sequences.
In the United States, GeoVax received patent No. 11,896,657 for a Modified Vaccinia Ankara (MVA) viral vector expressing Marburg virus proteins and patent No. 11,897,919 covering a multivalent HIV vaccine. These patents support GeoVax’s efforts in developing vaccines for Marburg virus and HIV, utilizing its MVA vector platform.
David Dodd, President and CEO of GeoVax, highlighted the addition of these patents to the company’s growing intellectual property, which now comprises over 115 granted or pending applications across 24 patent families. He emphasized the company’s focus on its next-generation Covid-19 vaccine currently in Phase 2 trials and its cancer immunotherapy program, with Gedeptin® for advanced head and neck cancer also in clinical trials.
While the company’s HIV program is not under active development, the patent protection for this vaccine remains a critical component of GeoVax’s technology platform. Dodd also mentioned the company’s commitment to advancing vaccines for lethal hemorrhagic fever viruses like the Marburg virus, recognized by the FDA Priority Review Voucher program.
The information in this article is based on a press release statement from GeoVax Labs, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.